Investor Contact
Financial PR and Investor Relations enquiries
Walbrook PR
75 King William Street
London
EC4N 7BE
Tel: 020 7933 8780
Email: polarean@walbrookpr.com
Latest News
-
FDA grants New Chemical Entity designation for XENOVIEW
01 February 2023
-
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized)
28 December 2022 -
Update on New Drug Application
30 September 2022
About Us
Latest Annual Report
Investor Alert
Sign up for Email Alerts